Trident Texofab Ltd. | Small-cap | Consumer Cyclical
₹212.60
-0.09%
| Trident Texofab Stock Comparison:
No comparison data available
Overview Income Statement Balance Sheet Cash Flow Key Ratios

Financial Overview

Latest Annual: 2025

Income Metrics

Revenue 1.2B
Gross Profit 162.3M 13.30%
Operating Income 38.2M 3.13%
Net Income 25.1M 2.06%

Balance Sheet Metrics

Total Assets 1.0B
Total Liabilities 533.4M
Shareholders Equity 472.4M
Debt to Equity 1.13

Cash Flow Metrics

Operating Cash Flow -106.0M
Free Cash Flow -137.1M

Revenue & Profitability Trend

Trident Texofab Income Statement From 2021 to 2025

Metric 2025 2024 2023 2022 2021
Revenue 1.2B 994.8M 963.6M 842.9M 499.3M
Cost of Goods Sold 1.1B 850.5M 815.8M 726.5M 424.6M
Gross Profit 162.3M 144.3M 147.8M 116.5M 74.6M
Operating Expenses 79.0M 38.2M 37.7M 31.7M 25.2M
Operating Income 38.2M 62.5M 65.7M 45.5M 18.6M
Pre-tax Income 25.8M 11.7M 27.3M 12.7M 9.0M
Income Tax 656.0K 889.0K 5.1M 2.9M 5.5M
Net Income 25.1M 10.8M 22.2M 9.8M 3.5M
EPS (Diluted) - ₹1.07 ₹2.20 ₹0.98 ₹0.35

Income Statement Trend

Trident Texofab Balance Sheet From 2021 to 2025

Metric 2025 2024 2023 2022 2021
Assets
Current Assets 737.4M 521.0M 466.9M 400.3M 400.0M
Non-Current Assets 268.3M 297.9M 306.2M 309.6M 277.8M
Total Assets 1.0B 819.0M 773.1M 709.9M 677.7M
Liabilities
Current Liabilities 407.5M 422.8M 372.3M 302.5M 302.3M
Non-Current Liabilities 125.9M 233.6M 249.0M 277.8M 255.6M
Total Liabilities 533.4M 656.4M 621.3M 580.3M 558.0M
Equity
Total Shareholders Equity 472.4M 162.6M 151.8M 129.6M 119.8M

Balance Sheet Composition

Trident Texofab Cash Flow Statement From 2021 to 2025

Metric 2025 2024 2023 2022 2021
Operating Activities
Net Income 25.8M 11.7M 27.3M 12.7M 9.0M
Operating Cash Flow -106.0M -3.7M -10.7M 33.4M 14.9M
Investing Activities
Capital Expenditures 0 -575.0K -2.2M -41.6M -99.2M
Investing Cash Flow 13.0M -7.0M 2.6M -56.7M -103.3M
Financing Activities
Dividends Paid - - - - -
Financing Cash Flow 181.3M 19.7M -25.7M 55.0M 111.8M
Free Cash Flow -137.1M 26.6M 56.4M -27.6M -79.6M

Cash Flow Trend

Trident Texofab Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 104.33
Price to Book 4.69
Price to Sales 2.67

Profitability Ratios

Profit Margin 2.06%
Operating Margin 2.47%
Return on Equity 7.91%
Return on Assets 2.62%

Financial Health

Current Ratio 1.81
Debt to Equity 62.67
Beta -1.38

Per Share Data

EPS (TTM) ₹2.08
Book Value per Share ₹46.27
Revenue per Share ₹115.73

Financial data is updated regularly. All figures are in the company's reporting currency.